Plasma metabolites predict severity of depression and suicidal ideation in psychiatric patients-a multicenter pilot analysis

Daiki Setoyama, Takahiro Kato, Ryota Hashimoto, Hiroshi Kunugi, Kotaro Hattori, Kohei Hayakawa, Mina Sato-Kasai, Norihiro Shimokawa, Sachie Kaneko, Sumiko Yoshida, Yu Ichi Goto, Yuka Yasuda, Hidenaga Yamamori, Masahiro Ohgidani, Noriaki Sagata, Daisuke Miura, Dongchon Kang, Shigenobu Kanba

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Evaluating the severity of depression (SOD), especially suicidal ideation (SI), is crucial in the treatment of not only patients with mood disorders but also psychiatric patients in general. SOD has been assessed on interviews such as the Hamilton Rating Scale for Depression (HAMD)-17, and/or self-administered questionnaires such as the Patient Health Questionnaire (PHQ)-9. However, these evaluation systems have relied on a person's subjective information, which sometimes lead to difficulties in clinical settings. To resolve this limitation, a more objective SOD evaluation system is needed. Herein, we collected clinical data including HAMD-17/PHQ-9 and blood plasma of psychiatric patients from three independent clinical centers. We performed metabolome analysis of blood plasma using liquid chromatography mass spectrometry (LC-MS), and 123 metabolites were detected. Interestingly, five plasma metabolites (3-hydroxybutyrate (3HB), betaine, citrate, creatinine, and gamma-aminobutyric acid (GABA)) are commonly associated with SOD in all three independent cohort sets regardless of the presence or absence of medication and diagnostic difference. In addition, we have shown several metabolites are independently associated with sub-symptoms of depression including SI. We successfully created a classification model to discriminate depressive patients with or without SI by machine learning technique. Finally, we produced a pilot algorithm to predict a grade of SI with citrate and kynurenine. The above metabolites may have strongly been associated with the underlying novel biological pathophysiology of SOD. We should explore the biological impact of these metabolites on depressive symptoms by utilizing a cross species study model with human and rodents. The present multicenter pilot study offers a potential utility for measuring blood metabolites as a novel objective tool for not only assessing SOD but also evaluating therapeutic efficacy in clinical practice. In addition, modification of these metabolites by diet and/or medications may be a novel therapeutic target for depression. To clarify these aspects, clinical trials measuring metabolites before/after interventions should be conducted. Larger cohort studies including non-clinical subjects are also warranted to clarify our pilot findings.

Original languageEnglish
Article numbere0165267
JournalPloS one
Volume11
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Suicidal Ideation
Metabolites
Psychiatry
Depression
metabolites
Plasmas
Blood
questionnaires
blood plasma
citrates
signs and symptoms (animals and humans)
drug therapy
Health
kynurenine
3-hydroxybutyric acid
Kynurenine
therapeutics
rating scales
3-Hydroxybutyric Acid
artificial intelligence

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Plasma metabolites predict severity of depression and suicidal ideation in psychiatric patients-a multicenter pilot analysis. / Setoyama, Daiki; Kato, Takahiro; Hashimoto, Ryota; Kunugi, Hiroshi; Hattori, Kotaro; Hayakawa, Kohei; Sato-Kasai, Mina; Shimokawa, Norihiro; Kaneko, Sachie; Yoshida, Sumiko; Goto, Yu Ichi; Yasuda, Yuka; Yamamori, Hidenaga; Ohgidani, Masahiro; Sagata, Noriaki; Miura, Daisuke; Kang, Dongchon; Kanba, Shigenobu.

In: PloS one, Vol. 11, No. 12, e0165267, 01.12.2016.

Research output: Contribution to journalArticle

Setoyama, D, Kato, T, Hashimoto, R, Kunugi, H, Hattori, K, Hayakawa, K, Sato-Kasai, M, Shimokawa, N, Kaneko, S, Yoshida, S, Goto, YI, Yasuda, Y, Yamamori, H, Ohgidani, M, Sagata, N, Miura, D, Kang, D & Kanba, S 2016, 'Plasma metabolites predict severity of depression and suicidal ideation in psychiatric patients-a multicenter pilot analysis', PloS one, vol. 11, no. 12, e0165267. https://doi.org/10.1371/journal.pone.0165267
Setoyama, Daiki ; Kato, Takahiro ; Hashimoto, Ryota ; Kunugi, Hiroshi ; Hattori, Kotaro ; Hayakawa, Kohei ; Sato-Kasai, Mina ; Shimokawa, Norihiro ; Kaneko, Sachie ; Yoshida, Sumiko ; Goto, Yu Ichi ; Yasuda, Yuka ; Yamamori, Hidenaga ; Ohgidani, Masahiro ; Sagata, Noriaki ; Miura, Daisuke ; Kang, Dongchon ; Kanba, Shigenobu. / Plasma metabolites predict severity of depression and suicidal ideation in psychiatric patients-a multicenter pilot analysis. In: PloS one. 2016 ; Vol. 11, No. 12.
@article{21c67bbebb81433d97db0abf161dae9c,
title = "Plasma metabolites predict severity of depression and suicidal ideation in psychiatric patients-a multicenter pilot analysis",
abstract = "Evaluating the severity of depression (SOD), especially suicidal ideation (SI), is crucial in the treatment of not only patients with mood disorders but also psychiatric patients in general. SOD has been assessed on interviews such as the Hamilton Rating Scale for Depression (HAMD)-17, and/or self-administered questionnaires such as the Patient Health Questionnaire (PHQ)-9. However, these evaluation systems have relied on a person's subjective information, which sometimes lead to difficulties in clinical settings. To resolve this limitation, a more objective SOD evaluation system is needed. Herein, we collected clinical data including HAMD-17/PHQ-9 and blood plasma of psychiatric patients from three independent clinical centers. We performed metabolome analysis of blood plasma using liquid chromatography mass spectrometry (LC-MS), and 123 metabolites were detected. Interestingly, five plasma metabolites (3-hydroxybutyrate (3HB), betaine, citrate, creatinine, and gamma-aminobutyric acid (GABA)) are commonly associated with SOD in all three independent cohort sets regardless of the presence or absence of medication and diagnostic difference. In addition, we have shown several metabolites are independently associated with sub-symptoms of depression including SI. We successfully created a classification model to discriminate depressive patients with or without SI by machine learning technique. Finally, we produced a pilot algorithm to predict a grade of SI with citrate and kynurenine. The above metabolites may have strongly been associated with the underlying novel biological pathophysiology of SOD. We should explore the biological impact of these metabolites on depressive symptoms by utilizing a cross species study model with human and rodents. The present multicenter pilot study offers a potential utility for measuring blood metabolites as a novel objective tool for not only assessing SOD but also evaluating therapeutic efficacy in clinical practice. In addition, modification of these metabolites by diet and/or medications may be a novel therapeutic target for depression. To clarify these aspects, clinical trials measuring metabolites before/after interventions should be conducted. Larger cohort studies including non-clinical subjects are also warranted to clarify our pilot findings.",
author = "Daiki Setoyama and Takahiro Kato and Ryota Hashimoto and Hiroshi Kunugi and Kotaro Hattori and Kohei Hayakawa and Mina Sato-Kasai and Norihiro Shimokawa and Sachie Kaneko and Sumiko Yoshida and Goto, {Yu Ichi} and Yuka Yasuda and Hidenaga Yamamori and Masahiro Ohgidani and Noriaki Sagata and Daisuke Miura and Dongchon Kang and Shigenobu Kanba",
year = "2016",
month = "12",
day = "1",
doi = "10.1371/journal.pone.0165267",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Plasma metabolites predict severity of depression and suicidal ideation in psychiatric patients-a multicenter pilot analysis

AU - Setoyama, Daiki

AU - Kato, Takahiro

AU - Hashimoto, Ryota

AU - Kunugi, Hiroshi

AU - Hattori, Kotaro

AU - Hayakawa, Kohei

AU - Sato-Kasai, Mina

AU - Shimokawa, Norihiro

AU - Kaneko, Sachie

AU - Yoshida, Sumiko

AU - Goto, Yu Ichi

AU - Yasuda, Yuka

AU - Yamamori, Hidenaga

AU - Ohgidani, Masahiro

AU - Sagata, Noriaki

AU - Miura, Daisuke

AU - Kang, Dongchon

AU - Kanba, Shigenobu

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Evaluating the severity of depression (SOD), especially suicidal ideation (SI), is crucial in the treatment of not only patients with mood disorders but also psychiatric patients in general. SOD has been assessed on interviews such as the Hamilton Rating Scale for Depression (HAMD)-17, and/or self-administered questionnaires such as the Patient Health Questionnaire (PHQ)-9. However, these evaluation systems have relied on a person's subjective information, which sometimes lead to difficulties in clinical settings. To resolve this limitation, a more objective SOD evaluation system is needed. Herein, we collected clinical data including HAMD-17/PHQ-9 and blood plasma of psychiatric patients from three independent clinical centers. We performed metabolome analysis of blood plasma using liquid chromatography mass spectrometry (LC-MS), and 123 metabolites were detected. Interestingly, five plasma metabolites (3-hydroxybutyrate (3HB), betaine, citrate, creatinine, and gamma-aminobutyric acid (GABA)) are commonly associated with SOD in all three independent cohort sets regardless of the presence or absence of medication and diagnostic difference. In addition, we have shown several metabolites are independently associated with sub-symptoms of depression including SI. We successfully created a classification model to discriminate depressive patients with or without SI by machine learning technique. Finally, we produced a pilot algorithm to predict a grade of SI with citrate and kynurenine. The above metabolites may have strongly been associated with the underlying novel biological pathophysiology of SOD. We should explore the biological impact of these metabolites on depressive symptoms by utilizing a cross species study model with human and rodents. The present multicenter pilot study offers a potential utility for measuring blood metabolites as a novel objective tool for not only assessing SOD but also evaluating therapeutic efficacy in clinical practice. In addition, modification of these metabolites by diet and/or medications may be a novel therapeutic target for depression. To clarify these aspects, clinical trials measuring metabolites before/after interventions should be conducted. Larger cohort studies including non-clinical subjects are also warranted to clarify our pilot findings.

AB - Evaluating the severity of depression (SOD), especially suicidal ideation (SI), is crucial in the treatment of not only patients with mood disorders but also psychiatric patients in general. SOD has been assessed on interviews such as the Hamilton Rating Scale for Depression (HAMD)-17, and/or self-administered questionnaires such as the Patient Health Questionnaire (PHQ)-9. However, these evaluation systems have relied on a person's subjective information, which sometimes lead to difficulties in clinical settings. To resolve this limitation, a more objective SOD evaluation system is needed. Herein, we collected clinical data including HAMD-17/PHQ-9 and blood plasma of psychiatric patients from three independent clinical centers. We performed metabolome analysis of blood plasma using liquid chromatography mass spectrometry (LC-MS), and 123 metabolites were detected. Interestingly, five plasma metabolites (3-hydroxybutyrate (3HB), betaine, citrate, creatinine, and gamma-aminobutyric acid (GABA)) are commonly associated with SOD in all three independent cohort sets regardless of the presence or absence of medication and diagnostic difference. In addition, we have shown several metabolites are independently associated with sub-symptoms of depression including SI. We successfully created a classification model to discriminate depressive patients with or without SI by machine learning technique. Finally, we produced a pilot algorithm to predict a grade of SI with citrate and kynurenine. The above metabolites may have strongly been associated with the underlying novel biological pathophysiology of SOD. We should explore the biological impact of these metabolites on depressive symptoms by utilizing a cross species study model with human and rodents. The present multicenter pilot study offers a potential utility for measuring blood metabolites as a novel objective tool for not only assessing SOD but also evaluating therapeutic efficacy in clinical practice. In addition, modification of these metabolites by diet and/or medications may be a novel therapeutic target for depression. To clarify these aspects, clinical trials measuring metabolites before/after interventions should be conducted. Larger cohort studies including non-clinical subjects are also warranted to clarify our pilot findings.

UR - http://www.scopus.com/inward/record.url?scp=85006832827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006832827&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0165267

DO - 10.1371/journal.pone.0165267

M3 - Article

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e0165267

ER -